Get started
REGENERON PHARMACEUTICALS INC COM STK USD0.001REGENERON PHARMACEUTICALS INC COM STK USD0.001REGENERON PHARMACEUTICALS INC COM STK USD0.001

REGENERON PHARMACEUTICALS INC COM STK USD0.001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0R2M trade ideas

Regeneron Pharma Inc Fast-track Covid-19 drugRegeneron announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated hundreds of virus-neutralizing, fully human antibodies from the company's VelocImmune mice, which have been genetically-modified to have a human immune system. Regeneron has also isolated antibodies from humans who have recovered from COVID-19, in order to maximize the pool of potentially potent antibodies. From this large pool of candidates, Regeneron will select the top two antibodies for a 'cocktail' treatment based on potency and binding ability to the SARS-CoV-2 spike protein, as well as other desirable qualities. Using a multi-antibody approach allows for targeting of different parts of the virus and may help protect against multiple viral variants. Regeneron previously used these technologies to rapidly develop a successful treatment for Ebola virus infection, which is currently under review by the U.S. FDA. In order to meet the pressing public health need, Regeneron is applying its VelociMab technology to prepare manufacturing-ready cell lines as lead antibodies are selected, so that clinical-scale production can begin immediately. The company is working toward the goal of producing hundreds of thousands of prophylactic doses per month by the end of summer and hopes to have smaller quantities available for initial clinical testing at the beginning of the summer. The company is working with the U.S. Health & Human Services' Biomedical Advanced Research and Defense Authority to increase capacity even further. "Our three decades of investment in our VelociSuite antibody technologies, which accelerate and improve the traditional drug discovery process, have hopefully prepared us for this critical time and to meet this important challenge," said George D. Yancopoulos, M.D., Ph.D., Co-founder, President and Chief Scientific Officer of Regeneron. "Given the tremendous interest and concern around the COVID-19 pandemic, we will be providing regular and transparent updates on our discovery and development programs. I want to recognize our incredible team, which is working around the clock to develop needed solutions to this global health crisis." All coronaviruses have a single glycoprotein on the virus surface called the spike protein, which is the protein on the virus cell surface that binds to the host cell and is required for infectivity. Regeneron's SARS-CoV-2 antibodies will target the spike protein in order to block its interaction with the host cell, and thus neutralize the virus. Source thefly.com
NASDAQ:REGN
by Bullishcharts
Spy weekend recap not much has changed on the daily on the $SPY but, the weekly. We are on the support so one or two ways traders should determine the outcome should we continue with the selling off or just accepted it and regain control of the situation? on the weekly what I would like to see in a flip and regain the sell off. If you saw my 3/5 (LINK) post then you get the idea. Let's go on the little adventure: $REGN (WKLY) up into retake the $522.96 territory? same with $GILD (Daily) $INO can this continue or reverse and puke ?
NASDAQ:REGN
by newsdesk